In its first acquisition following the collapse of the merger with Allergan, Pfizer has agreed to acquire US-based Anacor Pharmaceuticals for US$5.2 B. Through this deal, Pfizer’s inflammation and immunology drugs portfolio stands to gain crisaborole, a late stage non-steroidal topical gel registered for approval with the US FDA for atopic dermatitis, and Kerydin®, a topical treatment for toenail fungus, which is currently marketed by Sandoz in the US.